Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
September 22, 2022
Ryan Allway September 22nd, 2022 Psychedelics, Top News Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd. VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “Company“), a biotech... Read more
NeonMind Announces DTC Eligibility
August 25, 2021
Ryan Allway August 25th, 2021 Psychedelics VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) (“NeonMind” or the “Company”), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that its common shares... Read more
